Grifols
Catalan pharmaceutical company
GRF BME Madrid · home listing
GRFS Nasdaq
ISIN ES0171996012 LEI 959800HSSNXWRKBK4N60
Follow Grifols
Weekly email: filings, results
Revenue, last year
€7.5B
+4.3% vs prior year
Net income
€402M
+156.2% vs prior year
EPS, diluted
-
Operating cash flow
€1B
+16.1% vs prior year
Source: ESEF annual reports · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | €7.5B | €402M |
| FY24 | €7.2B | €156.9M |
| FY23 | €6.6B | €42.3M |
| FY22 | €6.1B | €208.3M |
| FY21 | €4.9B | €188.7M |
| FY20 | €5.3B | €618.5M |
| FY19 | €5.1B | €625.1M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 38% | 16.5% | 5.3% |
| FY24 | 38.7% | 16.5% | 2.2% |
| FY23 | 37.7% | 11.9% | 0.6% |
| FY22 | 36.8% | 13.3% | 3.4% |
| FY21 | 39.8% | 12.1% | 3.8% |
| FY20 | 42.2% | 18.7% | 11.6% |
| FY19 | 45.9% | 22.2% | 12.3% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | €782M |
| FY24 | €669.6M |
| FY23 | −€5.7M |
| FY22 | −€277.4M |
| FY21 | €349.6M |
| FY20 | €830.2M |
| FY19 | €258.6M |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | €128M | - |
| FY24 | €962K | €0 |
| FY23 | €0 | €0 |
| FY22 | €592K | €3.5M |
| FY21 | €258.9M | €125.7M |
| FY20 | €113.2M | - |
| FY19 | €238.7M | - |
- Grifols
- Healthcare median
Show the numbers
| Year | Grifols | Healthcare median |
|---|---|---|
| FY25 | 5.3% | −30.6% |
| FY24 | 2.2% | −47% |
| FY23 | 0.6% | −58% |
| FY22 | 3.4% | −80.4% |
| FY21 | 3.8% | −71.9% |
| FY20 | 11.6% | −62.2% |
| FY19 | 12.3% | −46.3% |